?
What combinations of molecular and digital biomarkers should become standard in platform trials?
active
open question
Created: 2026-04-25T20:29:12
By: backfill_open_questions
Quality:
50%
✓ SciDEX
ID: open_question-9f118a5b-0d02-423a-a8ed-2e
Open Question
open
Wiki: diseases-als-progression-rate-heterogeneity
What combinations of molecular and digital biomarkers should become standard in platform trials?
Importance Elo
1500
Field Rank
Rank #226 in diseases
Tractability
0.50
Potential Impact
0.50
Evidence Summary
Extracted from wiki page diseases-als-progression-rate-heterogeneity
Secondary Market
No secondary market activity yet. Learn about share issuance →
Share Holder Leaderboard
No shares issued yet.
Evidence Bearing On This Question
No cross-references found yet. Evidence matching runs daily.
Pairwise Tournament History
No pairwise judgments recorded yet.
Derived Hypotheses And Proposals
No derived artifacts linked yet.
Related Entities
▸Metadata
| status | open |
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-26T03:29:12.201677'} |
| field_tag | diseases |
| source_id | diseases-als-progression-rate-heterogeneity |
| sub_field | als-progression-rate-heterogeneity |
| source_kind | wiki |
| question_hash | ac3a6b89ca8e4e0ee59c2559b72e195345b1e24606f7b26074a820333b593406 |
| question_text | What combinations of molecular and digital biomarkers should become standard in platform trials? |
| importance_elo | 1500 |
| _schema_version | 1 |
| evidence_summary | Extracted from wiki page diseases-als-progression-rate-heterogeneity |
| tractability_score | 0.5 |
| potential_impact_score | 0.5 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.